CagriSema and tirzepatide target different hormone receptors, and their U.S. regulatory status differs: tirzepatide is available as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, while Novo Nordisk reported CagriSema was still under FDA review for weight management as of October 4, 2026. Both have produced substantial weight loss in clinical trials, but the results do not establish which treatment is best for an individual or show that CagriSema and tirzepatide control diabetes equally well.
How do CagriSema and tirzepatide work?
CagriSema combines two hormone-targeting medicines
CagriSema is Novo Nordisk’s once-weekly injectable combination of cagrilintide 2.4 mg and semaglutide 2.4 mg. Semaglutide activates the GLP-1 receptor; cagrilintide is a long-acting amylin analogue. Novo Nordisk says the combination reduces hunger, increases fullness and helps people eat less, lowering calorie intake.
As an Amazon Associate I earn from qualifying purchases.
Tirzepatide activates GIP and GLP-1 receptors
Tirzepatide acts on both the GIP and GLP-1 receptors. In the United States, it is given by weekly injection, with gradual dose escalation described in the current Zepbound prescribing information. The molecule is sold under two brand names for different approved uses: Mounjaro for type 2 diabetes and Zepbound for chronic weight management in eligible adults.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Clear out junk files and repair common Windows errors3Fix the driver behind crashes, sound loss and screen glitchesWhat is their U.S. approval status?
As of October 4, 2026, tirzepatide has FDA-approved brands for type 2 diabetes and chronic weight management. Novo Nordisk reported that it submitted CagriSema to the FDA for weight management in December 2025 and anticipated a decision by late 2026. Until the FDA acts, CagriSema remains investigational in the United States; the submission and anticipated timing are the developer’s statements, not an FDA approval.
#1 Best Overall
- 12 MONTH WEIGHT LOSS TRACKER Track your weight loss journey over 12 months with a guided journal designed for recording pounds lost, body measurements, goals and progress.
- POUNDS LOST & BODY MEASUREMENTS Includes 10, 20, 30, 50 and 100 pounds lost trackers, plus body measurement tracking to help you visually follow your progress over time.
- MONTHLY STEP & FITNESS TRACKERS Plan and record movement with monthly step trackers and monthly fitness planner pages, ideal for building consistency around activity and fitness goals.
- VITAMINS, SUPPLEMENTS & REFLECTIONS Includes vitamins and supplements trackers, plus goals and reflections sections to help you stay organised and review your progress throughout the year.
- CHALLENGES TO KEEP YOU MOTIVATED Features 30 day, 12 week and 52 week challenges, giving you different ways to stay focused and create momentum across your weight loss journey.
Regulatory status and indications can differ outside the United States. Check the relevant national regulator and local product information rather than assuming U.S. approvals apply elsewhere.
What do the weight-loss trials show?
The results below are averages from selected trial populations, not predictions of what a particular person will lose. Study duration, participants, comparators and analysis methods differ, so percentages from separate trials are not a fair direct ranking.
Rank #2
- FOOD JOURNAL FOR HEALTHY - A food journal to tracks daily dietary and nutritional intake for women/men. It will help you stay healthy, get motivated, get rid of bad habits, and achieve your weight loss goals. Focus on your health and eat healthy, this food tracker is all about what you want to improve.
- ACHIEVE GOALS - This fitness and nutrition journal helps you set big goals, break them down into monthly milestones, and work relentlessly toward them. At the end of each month, you will complete a monthly review to reflect your progress.
- UNDATED 6 MONTH MEAL PLANNER - This is a food diary that tracks meals and exercise last for 6 month. Keep daily records of calories, sleep time, water, weight, body fat, and activity. The monthly record can help you pay attention to your health and notice how changing your diet and lifestyle affects how you feel.
- ADDITIONAL - Lovely patterns created by hardcover, high quality of size 5.8" x 8.3", There are 3 sheets colorful stickers to help you plan and stay motivated to continue using this daily journal. What's more, the food journal with 3 ribbon bookmark, elastic band, pen holder and inner pocket for easy use.
- GUARANTEE - If you have any problems with this food journal, please contact us and we will help you solve promptly!
| Trial and treatment | Population, design and duration | Reported average weight change |
|---|---|---|
| REDEFINE 1: CagriSema versus placebo | Phase 3 trial of adults with obesity or overweight plus at least one weight-related complication, without type 2 diabetes; 68 weeks. | Estimated mean change at week 68: −20.4% with CagriSema versus −3.0% with placebo. REDEFINE 1 investigators, The New England Journal of Medicine, 2025. |
| REDEFINE 4: CagriSema versus tirzepatide 15 mg | Novo Nordisk-reported, 84-week open-label comparison; 809 people with obesity and at least one comorbidity were randomized. Both treatments were once-weekly subcutaneous injections; CagriSema was 2.4 mg/2.4 mg. | At week 84, the estimate assuming adherence was −23.0% with CagriSema and −25.5% with tirzepatide. Under the treatment-regimen estimand, which accounts for treatment discontinuation, estimates were −20.2% and −23.6%, respectively. Novo Nordisk, 2026. |
| FDA pivotal-trial context: Zepbound | FDA’s 2023 approval announcement described separate randomized, double-blind, placebo-controlled trials. Results were reported at 72 weeks for adults without diabetes and adults with type 2 diabetes, at the highest approved dose. | Average body-weight reduction was 18% in the trial population without diabetes and 12% in the population with type 2 diabetes. U.S. Food and Drug Administration, 2023. |
REDEFINE 4 is the direct comparison in this evidence set, but it was open-label and the results above were reported by CagriSema’s developer. The two estimates answer different analysis questions: the adherence estimate assumes treatment adherence, while the treatment-regimen estimate includes the effects of discontinuation. Neither is a guarantee of an individual outcome or, by itself, proof that one treatment will work better for every patient.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Can you compare them for diabetes treatment?
The evidence summarized here does not establish a like-for-like comparison of blood-sugar control between CagriSema and tirzepatide. The weight-loss trials cited above involved different populations and were not a direct test of diabetes outcomes. Tirzepatide is approved in the United States as Mounjaro for type 2 diabetes; CagriSema’s reported FDA submission is for weight management. Do not interpret weight loss in a trial as proof of diabetes remission or equivalent glucose control.
For people with diabetes, a clinician can assess the appropriate treatment goal and how a medicine fits with existing medicines. The current Zepbound label advises glucose monitoring in patients with diabetes and monitoring for progression in people with a history of diabetic retinopathy.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What safety information matters?
The current U.S. Zepbound prescribing information lists nausea, diarrhea, vomiting, constipation, abdominal pain and indigestion among common adverse reactions. It also warns about severe gastrointestinal reactions, gallbladder disease, pancreatitis, kidney injury related to volume depletion, and low blood sugar when tirzepatide is used with insulin or an insulin secretagogue.
Rank #4
- 150-day/5-month food and fitness journal with measuring tape: this fitness journal allows you to record up to 150 days of fitness and diet data, ensuring you stay on track with your health goals. The measuring tape helps you to track your body dimensions and detailed tracking system helps you monitor progress and make necessary adjustments to your routine
- Structured goal setting and achievement: the 2 goal pages of fitness planner has 10 sections for setting clear objectives, start and end dates, detailed plans, and results. The workout journal also features a reward section to motivate you to achieve your fitness milestones
- Body dimension contrasts by table, photos and chart: the body dimension contrasts can be shown by figures, photos, and progress curves. This visual representation allows you to see tangible changes in your physique over time, providing motivation and a clear sense of achievement
- Integrated calendar and daily tracking: the 2-page undated calendar of weight loss journal provides a monthly overview with daily completion marks and progress curves. The daily tracking pages allow you to log specific exercises, calories burned, and meal calorie intake. This integrated system helps you maintain a consistent routine and stay accountable to your fitness and nutrition goals
- User-friendly design, durable material: the 9.5'' * 7'' fitness journal for women is easy to carry and use, with a waterproof and sweat-proof PP material cover and ink-resistant 100gsm thick paper inside. The elastic band keeps the workout planner closed to keep your data private and organized. Double sided pockets are designed for cards, guidebooks, etc.
The label carries a boxed warning about thyroid C-cell tumors observed in rats. Zepbound is contraindicated for people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 (MEN2). These are tirzepatide label statements; the information here does not establish that CagriSema has the same safety profile.
The FDA says Zepbound should not be combined with Mounjaro or a GLP-1 receptor agonist. Do not treat the brand names or these medicines as interchangeable or combine them without a prescriber’s direction.
Quick Recap
Best Value
- SMASH YOUR PB'S - Achieve the performance and physique you've always wanted with Nextnoid daily workout journal! Effectively track both daily and weekly workout goals upto 8 months as meticulously as you desire, plan next week's workouts, and celebrate your success with ease. Stay focused!
- GET FITTER, FASTER - Take control of your health and fitness journey and accelerate your results with our fitness planner for women and men! This exercise diary provides you with a proven system to build muscle, improve strength or just be healthier. What gets measured, improves!
- SIMPLE AND CLEAR - Setting yourself up for success has never been easier! Our personal workout book takes the thought and effort out of staying disciplined and accountable with a clear incremental progress system, bigger fonts for easy reading and enough space to jot down everything.
- CAREFULLY CRAFTED - Made with functionality and also long-lasting durability in mind with size 5.7x8.3 in, this fit log journal is tough enough to withstand the rigors of the gym floor, running trail and even the kitchen! Premium thick 120gsm pages and a sweat and tear-proof outer match your grit!
- PERFECT GIFT - Show the fitness enthusiast in your life just how much you care with this workout tracker notebook! Also ideal for the beginner who dreams of being in shape, this fitness training journal could be the motivation they need to kickstart their health and wellness journey!
What should guide a treatment discussion?
- Approval and intended use: distinguish an approved treatment from one still under review, and confirm the indication in your country.
- Your health and other medicines: review relevant medical history, risks and current treatments with a clinician; diabetes medicines may require monitoring or adjustment.
- Evidence that matches your question: compare participants, dose, study duration, comparator and analysis method—not just the headline percentage.
- Your individual response: trial averages cannot predict an individual result, and tolerability and treatment goals also matter.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
